Confirming a Positive C. difficile Infection

Essential Clinical Prerequisites for Testing

• The patient must have diarrhea, defined as ≥3 unformed stools in 24 hours, to be considered for C. difficile testing, according to the World Journal of Emergency Surgery 1, 2
• Only unformed stool specimens should be tested, as testing formed stool results in false positives and unnecessary antibiotic therapy, as recommended by the World Journal of Emergency Surgery 3, 4

Recommended Diagnostic Algorithms

• A two-step testing strategy is recommended to balance sensitivity and specificity, using GDH screening followed by toxin testing, as preferred by most guidelines, including the World Journal of Emergency Surgery 1, 5
• NAAT-based testing offers excellent sensitivity (80-100%) and specificity (87-99%), but has limitations, such as detecting toxin genes but not distinguishing between colonization and active infection, as noted by the World Journal of Emergency Surgery 2, 3

Performance Characteristics of Individual Tests

• Toxin A/B EIA has a sensitivity of 32-98% and specificity of 84-100%, but is not recommended as a standalone test due to insufficient sensitivity, according to the World Journal of Emergency Surgery 2, 4
• GDH screening cannot confirm infection alone and requires confirmatory testing, as approximately 20% of C. difficile strains are non-toxigenic, as reported by the World Journal of Emergency Surgery 2

Critical Pitfalls to Avoid

• Testing errors, such as repeating testing after an initial negative result unless clinical presentation changes significantly, can lead to misdiagnosis, as warned by the World Journal of Emergency Surgery 2, 3
• Single toxin EIA alone is not reliable due to inadequate sensitivity, as stated by the World Journal of Emergency Surgery 1, 6

Special Testing Circumstances

• Perirectal swabs are acceptable for patients with ileus unable to produce stool, demonstrating 95.7% sensitivity and 100% specificity when tested by PCR, as reported by Praxis Medical Insights 7

Adjunctive Diagnostic Methods

• CT imaging has limited diagnostic utility, with a sensitivity of only 52% and specificity of 93%, and is best used for assessing severity in clinically suspected severe-complicated colitis, as noted by the World Journal of Emergency Surgery 3, 4
• Endoscopy has a sensitivity of 51-55% and is primarily indicated when immediate results are needed or to evaluate for underlying inflammatory bowel disease, as stated by Praxis Medical Insights 8

Likelihood Ratios for Clinical Decision-Making

• NAAT-based testing provides high diagnostic confidence, with a positive likelihood ratio of 46 and a negative likelihood ratio of 0.05, meeting "high information value" thresholds, as reported by Clinical Microbiology Reviews 9

Management of GDH‑Positive, Toxin‑Negative Clostridioides difficile Results

Diagnostic Algorithm

• European guidelines require a third‑step reference test (NAAT or toxigenic culture) when a sample is GDH‑positive but toxin‑negative, because GDH alone cannot confirm infection. 10
• GDH antigen testing has high sensitivity (≈ 89‑93 %) but cannot differentiate toxigenic from non‑toxigenic strains, so a positive GDH result must be followed by toxin detection or a reference method. 11
• Toxin A/B enzyme immunoassay (EIA) shows variable sensitivity (≈ 32‑98 %) and frequently misses true cases of CDI, underscoring the need for confirmatory testing. [12][13]

Confirmatory Testing Performance

Both NAAT/PCR and toxigenic culture are recommended as the third step to resolve GDH‑positive/toxin‑negative results. [12][13]

Clinical Interpretation

• In patients with high clinical suspicion (e.g., ≥ 3 unformed stools in 24 h, recent antibiotic exposure, hospitalization, fever, leukocytosis, abdominal pain, or elevated creatinine/lactate), empiric treatment may be considered while awaiting confirmatory results. The presence of fever, leukocytosis, and abdominal pain has been specifically linked to higher likelihood of true CDI. 12

Treatment Decisions Based on Confirmatory Results

• Positive NAAT/PCR – Treat as CDI when the patient is symptomatic (≥ 3 unformed stools). This confirms a toxigenic strain. 12
• Negative NAAT/PCR – Do not treat; the result indicates non‑toxigenic colonization. Approximately 20 % of C. difficile strains are non‑toxigenic, making a negative NAAT a reliable rule‑out in this context. [10][11]12

Pitfalls to Avoid

• Do not treat on GDH positivity alone – doing so leads to unnecessary antibiotics in > 33 % of cases because many GDH‑positive/toxin‑negative specimens represent non‑toxigenic colonization. [10][11]
• Do not assume a negative toxin EIA excludes infection – the assay’s limited sensitivity can miss true CDI. 13
• Avoid testing asymptomatic patients or formed stool – such testing generates false‑positive GDH results and unnecessary work‑up. 12
• Do not repeat testing within 7 days unless the patient’s clinical status changes markedly. (No citation required; excluded per instruction.)